| Revision as of 00:43, 13 December 2010 editEdgar181 (talk | contribs)Extended confirmed users196,325 edits added Category:Pyridines; removed {{uncategorized}} using HotCat← Previous edit | Revision as of 06:13, 19 April 2011 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (Next edit → | ||
| Line 1: | Line 1: | ||
| {{drugbox | {{drugbox | ||
| | verifiedrevid = 402053704 | |||
| | IUPAC_name = (E)-2-methyl-6-(2-phenylethenyl)pyridine | | IUPAC_name = (E)-2-methyl-6-(2-phenylethenyl)pyridine | ||
| | image = SIB-1893_structure.png | | image = SIB-1893_structure.png | ||
Revision as of 06:13, 19 April 2011
Pharmaceutical compound | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H13N |
| Molar mass | 195.259 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
| (verify) | |
SIB-1893 is a drug used in scientific research which was one of the first compounds developed that acts as a selective antagonist for the metabotropic glutamate receptor subtype mGluR5. It has anticonvulsant and neuroprotective effects, and reduces glutamate release. It has also been found to act as a positive allosteric modulator of mGluR4.
References
- Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Veliçelebi G, Johnson EC (1999). "SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5". The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 170–81. PMID 10381773.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Chapman AG, Nanan K, Williams M, Meldrum BS (2000). "Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893)". Neuropharmacology. 39 (9): 1567–74. doi:10.1016/S0028-3908(99)00242-7. PMID 10854901.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Wang SJ, Sihra TS (2004). "Noncompetitive metabotropic glutamate5 receptor antagonist (E)-2-methyl-6-styryl-pyridine (SIB1893) depresses glutamate release through inhibition of voltage-dependent Ca2+ entry in rat cerebrocortical nerve terminals (synaptosomes)". The Journal of Pharmacology and Experimental Therapeutics. 309 (3): 951–8. doi:10.1124/jpet.103.064881. PMID 14982967.
{{cite journal}}: Unknown parameter|month=ignored (help) - Mathiesen JM, Svendsen N, Bräuner-Osborne H, Thomsen C, Ramirez MT (2003). "Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP". British Journal of Pharmacology. 138 (6): 1026–30. doi:10.1038/sj.bjp.0705159. PMC 1573757. PMID 12684257.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |